Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients with Large Vessel Occlusion

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 242 participants.

Also called NCT04454788

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 242 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04454788
Other papers using this trial's data
  • Efficacy of Tenecteplase in Large Vessel Occlusion Stroke Within 24 Hours of Symptom Onset: The ETERNAL-LVO Randomized Controlled Trial Stroke, 2025-12 DOI, PubMed 40927857

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT04454788. Randomized; no masking; primary purpose treatment. Start 2020-08-01 (actual); primary completion 2024-07-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients with Large Vessel Occlusion
Acronym
ETERNAL-LVO
Intervention (Drug)
Tenecteplase
Intervention (Drug)
Standard Care (which may include intravenous Alteplase)
Lead sponsor
University of Melbourne (class: other)
Collaborator
Professor Mark Parsons (class: not stated)

Record details

Record id
cardio:ct-nct04454788
Content hash
301df9b8c26614689fd81e97a2090d1a5cf8f6c5d6e7e6299504140ed07c05fa